Claire Paquet, France
Assistance Publique Hôpitaux de Paris Center of Cognitive NeurologyAuthor Of 1 Presentation
DIAGNOSTIC PERFORMANCE OF BLOOD BIOMARKERS FOR ALZHEIMER’S DISEASE IN AN UNSELECTED MEMORY CLINIC COHORT
Abstract
Aims
To compare the diagnostic performance of plasma biomarkers for Alzheimer’s disease (AD) diagnosis in a diverse memory clinic setting.
Methods
We compared two recently developed plasma p-tau Single molecule array assays (p-tau181 and p-tau231), plasma neurofilament light (NfL) and plasma amyloid ratio (Aβ42/40) in diagnosing AD and identifying amyloid positivity, in 310 subjects: 32 controls, 60 with AD related mild cognitive impairment (MCI) and 104 with AD-dementia, 31 non-AD dementia’s (Lewy body dementia, frontotemporal dementia and vascular dementia), and 83 with non-AD related MCI. Patients were recruited in a memory clinic setting (Hospital Lariboisière, Paris, France).
Results
P-tau181, p-tau231 and NfL demonstrated high accuracy in identifying AD compared to controls (p-tau181: AUC=88.7%; p-tau231: AUC=85.4%; NFL: AUC=84.4%), performing better than amyloid ratio (AUC=70.2%). P-tau231 and p-tau181 also distinguished AD-MCI from controls (p-tau181: AUC=78.6%; p-tau231: AUC=78.4%). Both tau biomarkers separated amyloid+ from amyloid– patients (p-tau181: AUC=80.48%; p-tau231: AUC=80.31%), with higher accuracy than NfL (AUC=65.8%) and amyloid ratio (67.8%). P-tau181 and p-tau231 also distinguished AD from non-AD dementia (p-tau231: AUC=82.72%; p-tau181: AUC=81.22%), as opposed to NfL (AUC=57.78%).
Conclusions
Plasma p-tau181 and p-tau231 accurately identified AD at MCI and dementia stages of the disease, and efficiently distinguished AD dementia from non-AD dementia in a clinical setting. These could be simple and accessible tests for AD screening and diagnosis.